Optimize CGT Patient Journey White Paper

Optimizing the Cell and Gene Therapy Patient Journey Through Integrated CRO/CDMO Partnership

Cell and gene therapies (CGTs) have the potential to transform medicine across a spectrum of disease areas characterized by substantial need for novel treatment modalities. The clinical trials landscape for these cutting-edge therapies is intricate, encompassing numerous touchpoints, diverse providers and locations, and considerable expenses — factors that can negatively affect the patient journey.

Addressing these complexities demands a concerted effort in development and manufacturing strategies — as well as a patient-centric approach to trial design — overseen by a collaborative contract development and manufacturing organization (CDMO) and contract research organization (CRO).

This white paper delves into the importance of a unified approach to clinical development, which streamlines logistical and operational intricacies and prioritizes the patient experience, fostering greater accessibility and alleviating burdens associated with clinical trials.